Platelet production increases in anemic people. In particular, iron deficiency causes reactive thrombocytosis in such patients. Although anemia and iron deficiency are frequently seen in dogs, there are no published studies on this subject. The aim of the present study was to investigate the relationship between anemia, iron deficiency, and platelet production in dogs. A total of 81 dogs brought to the university animal hospital with signs of anemia were used. Haemogram parameters, serum iron (Fe), erythropoietin (EPO), and thrombopoietin (TPO) levels, as well as total iron binding capacity (TIBC), were measured. Transferrin saturation (TSAT) ratios were calculated. The animals were categorized as anemic or non-anemic, mildly anemic or moderately/ severely anemic, and having iron deficiency or no iron deficiency according to haemogram parameters and the serum Fe level. A high platelet number was observed in dogs with mild anemia. Dogs with mild anemia also had higher serum EPO levels than dogs with moderate/severe anemia (P = 0.047). Iron deficiency was detected in 31 dogs. The platelet number was higher in dogs with iron deficiency (P = 0.004). It was also observed that dogs with iron deficiency had higher serum EPO levels (P = 0.027) and lower TPO levels (P = 0.025) than dogs without iron deficiency. In conclusion, it can be said that mild anemia and iron deficiency cause thrombocytosis in dogs. The increased serum EPO levels, both in dogs with mild anemia and those with iron deficiency, suggest that the increase in platelet production is due to EPO. Nevertheless, there is a need for further research to fully understand the underlying mechanism.
Introduction and Aims: Oxidative stress may play a critical role in the pathogenesis of endothelial dysfunction in patients with diabetes or hypertension. Angiotensin converting enzyme inhibitors (ACEI), angiotensin II type 1 receptor blockers (ARB) and third generation beta-blockers, including carvedilol, have beneficial effects on oxidative stress beyond their antihypertensive and antiproteinuric properties. This study was aimed to evaluate short-term effects of losartan (ARB) therapy alone and together with cilazapril (ACEI) or carvedilol on oxidative stress and antioxidants in patients with type 2 diabetes mellitus, microalbuminuria and stage 1 hypertension. Methods: Fifty-six patients were enrolled and only 30 of the patients completed the study. After 2 weeks follow-up period, all patients received losartan 50 mg/day as a single dose for 6 weeks. Then, patients were randomized into 3 groups at the end of 6th week. Losartan dose was increased to 100 mg/day in the first group, and carvedilol (25 mg/day) was added in the second group and cilazapril (5 mg/day) in the third group to losartan 50 mg/day treatment for another 6 weeks. Oxidation and oxidizability of apolipoprotein B-containing lipoproteins (malondialdehyde: α-MDA, nmol MDA/mg chol, a lipid peroxidation biomarker of oxidative stress), activities of paraoxonase (PON, U/L) and arylesterase (AE, kU/L) (components of the antioxidant system), erythrocyte superoxide dismutase (SOD) and glutathione peroxidase (GSHPx)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.